Literature DB >> 22585010

Venous thromboembolism in patients with Cushing's syndrome: need of a careful investigation of the prothrombotic risk profile.

S Koutroumpi1, V Daidone, M T Sartori, M G Cattini, N M Albiger, G Occhi, S Ferasin, A Frigo, F Mantero, A Casonato, C Scaroni.   

Abstract

A high incidence of venous thromboembolic (VTE) complications has been reported in Cushing's syndrome (CS), mostly post-operatively and attributable to hypercoagulability. The prevalence of symptomatic VTE was investigated retrospectively in 58 consecutive CS patients in relation to acquired and genetic thrombotic risk factors. Eight CS patients (14 %) developed VTE (group A), 3 of them related and 5 unrelated to surgery. These patients had higher urinary free cortisol (p = 0.01) and VWF levels (p = 0.02) than the 50 patients without VTE (group B), as well an increase in the hemostatically more efficient, high-molecular-weight VWF multimers (p = 0.002). Factor V Leiden and the prothrombin gene 20210A variants (the most common inherited thrombophilic defects) were more represented in group A than in group B, as was the genotype GCAG/GCAG of the VWF gene promoter, known to hyperinduce VWF upregulation under cortisol excess. All but one of the patients with VTE unrelated to surgery had at least four acquired and at least one inherited risk factor. Severe hypercortisolism and VWF levels with increased haemostatic activity are strongly associated with VTE in CS. VTE episodes unrelated to surgery are attributable to the synergistic action of acquired and inherited thrombotic risk factors. Based on these observations, we believe that severely affected CS patients should be screened for coagulation disorders and receive antithrombotic prophylaxis whenever they have concomitant prothrombotic risk factors.

Entities:  

Mesh:

Year:  2013        PMID: 22585010     DOI: 10.1007/s11102-012-0398-4

Source DB:  PubMed          Journal:  Pituitary        ISSN: 1386-341X            Impact factor:   4.107


  33 in total

1.  "Pseudo homozygous" activated protein C resistance due to double heterozygous factor V defects (factor V Leiden mutation and type I quantitative factor V defect) associated with thrombosis: report of two cases belonging to two unrelated kindreds.

Authors:  P Simioni; A Scudeller; P Radossi; S Gavasso; B Girolami; D Tormene; A Girolami
Journal:  Thromb Haemost       Date:  1996-03       Impact factor: 5.249

2.  Cardiovascular risk factors and venous thromboembolism incidence: the longitudinal investigation of thromboembolism etiology.

Authors:  Albert W Tsai; Mary Cushman; Wayne D Rosamond; Susan R Heckbert; Joseph F Polak; Aaron R Folsom
Journal:  Arch Intern Med       Date:  2002-05-27

3.  Changes in coagulation indexes and occurrence of venous thromboembolism in patients with Cushing's syndrome: results from a prospective study before and after surgery.

Authors:  Luca Manetti; Fausto Bogazzi; Clara Giovannetti; Valentina Raffaelli; Maura Genovesi; Giovanni Pellegrini; Lucia Ruocco; Aldo Iannelli; Enio Martino
Journal:  Eur J Endocrinol       Date:  2010-08-09       Impact factor: 6.664

4.  Anticoagulant prophylaxis markedly reduces thromboembolic complications in Cushing's syndrome.

Authors:  Marco Boscaro; Nicoletta Sonino; Alessandro Scarda; Luisa Barzon; Francesco Fallo; Maria T Sartori; Giovanni M Patrassi; Antonio Girolami
Journal:  J Clin Endocrinol Metab       Date:  2002-08       Impact factor: 5.958

5.  World distribution of factor V Leiden.

Authors:  D C Rees; M Cox; J B Clegg
Journal:  Lancet       Date:  1995-10-28       Impact factor: 79.321

6.  The PAI-1 gene 4G/5G polymorphism and deep vein thrombosis in patients with inherited thrombophilia.

Authors:  Maria Teresa Sartori; Cristina Danesin; Graziella Saggiorato; Daniela Tormene; Paolo Simioni; Luca Spiezia; Giovanni Maurizio Patrassi; Antonio Girolami
Journal:  Clin Appl Thromb Hemost       Date:  2003-10       Impact factor: 2.389

7.  Hyperprothrombinemia associated with prothrombin G20210A mutation inhibits plasma fibrinolysis through a TAFI-mediated mechanism.

Authors:  Mario Colucci; Bianca M Binetti; Armando Tripodi; Veena Chantarangkul; Nicola Semeraro
Journal:  Blood       Date:  2003-11-20       Impact factor: 22.113

8.  Polymorphisms in von Willebrand factor gene promoter influence the glucocorticoid-induced increase in von Willebrand factor: the lesson learned from Cushing syndrome.

Authors:  Alessandra Casonato; Viviana Daidone; Francesca Sartorello; Nora Albiger; Chiara Romualdi; Franco Mantero; Antonio Pagnan; Carla Scaroni
Journal:  Br J Haematol       Date:  2008-01       Impact factor: 6.998

9.  Cardiovascular risk factors and venous thromboembolism: a meta-analysis.

Authors:  Walter Ageno; Cecilia Becattini; Timothy Brighton; Rita Selby; Pieter W Kamphuisen
Journal:  Circulation       Date:  2007-12-17       Impact factor: 29.690

10.  Markers of activation of coagulation and fibrinolysis in patients with Cushing's syndrome.

Authors:  L M Fatti; B Bottasso; C Invitti; R Coppola; F Cavagnini; P M Mannucci
Journal:  J Endocrinol Invest       Date:  2000-03       Impact factor: 5.467

View more
  10 in total

1.  Perioperative thromboprophylaxis in Cushing's disease: What we did and what we are doing?

Authors:  Mattia Barbot; Viviana Daidone; Marialuisa Zilio; Nora Albiger; Linda Mazzai; Maria Teresa Sartori; Anna Chiara Frigo; Massimo Scanarini; Luca Denaro; Marco Boscaro; Sandra Casonato; Filippo Ceccato; Carla Scaroni
Journal:  Pituitary       Date:  2015-08       Impact factor: 4.107

2.  A venous thromboembolism risk assessment model for patients with Cushing's syndrome.

Authors:  Marialuisa Zilio; Linda Mazzai; Maria Teresa Sartori; Mattia Barbot; Filippo Ceccato; Viviana Daidone; Alessandra Casonato; Graziella Saggiorato; Franco Noventa; Laura Trementino; Paolo Prandoni; Marco Boscaro; Giorgio Arnaldi; Carla Scaroni
Journal:  Endocrine       Date:  2015-06-26       Impact factor: 3.633

3.  CUSHING'S SYNDROME, A RISK FACTOR FOR VENOUS THROMBOEMBOLISM IS A CANDIDATE FOR GUIDELINES.

Authors:  G Koraćević; M Stojanović; S Petrović; D Simić; D Sakač; M Vlajković; M Stevic; M Kocić; M Đorđević; M Koraćević
Journal:  Acta Endocrinol (Buchar)       Date:  2020 Apr-Jun       Impact factor: 0.877

4.  Hypercoagulability in patients with Cushing disease detected by thrombin generation assay is associated with increased levels of neutrophil extracellular trap-related factors.

Authors:  Armando Tripodi; Concetta T Ammollo; Fabrizio Semeraro; Mario Colucci; Elena Malchiodi; Elisa Verrua; Emanuele Ferrante; Giorgio Arnaldi; Laura Trementino; Lidia Padovan; Veena Chantarangkul; Flora Peyvandi; Giovanna Mantovani
Journal:  Endocrine       Date:  2016-07-22       Impact factor: 3.633

5.  Thrombin generation in Cushing's Syndrome: do the conventional clotting indices tell the whole truth?

Authors:  S Koutroumpi; L Spiezia; N Albiger; M Barbot; M Bon; S Maggiolo; S Gavasso; P Simioni; A Frigo; F Mantero; C Scaroni
Journal:  Pituitary       Date:  2014-02       Impact factor: 4.107

6.  Is VTE Prophylaxis Necessary on Discharge for Patients Undergoing Adrenalectomy for Cushing Syndrome?

Authors:  Bruna Babic; Amory De Roulet; Anita Volpe; Naris Nilubol
Journal:  J Endocr Soc       Date:  2018-12-12

7.  Venous thromboembolism chemical prophylaxis after endoscopic trans-sphenoidal pituitary surgery.

Authors:  Mueez Waqar; Annabel Chadwick; James Kersey; Daniel Horner; Tara Kearney; Konstantina Karabatsou; Kanna K Gnanalingham; Omar N Pathmanaban
Journal:  Pituitary       Date:  2021-11-29       Impact factor: 4.107

8.  Current clinical practice for thromboprophylaxis management in patients with Cushing's syndrome across reference centers of the European Reference Network on Rare Endocrine Conditions (Endo-ERN).

Authors:  F M van Haalen; M Kaya; I C M Pelsma; O M Dekkers; N R Biermasz; S C Cannegieter; M V Huisman; B J M van Vlijmen; R A Feelders; F A Klok; A M Pereira
Journal:  Orphanet J Rare Dis       Date:  2022-05-03       Impact factor: 4.303

9.  Residual manifestations of hypercortisolemia following surgical treatment in a patient with Cushing syndrome.

Authors:  Sara K Bartz; Lefkothea P Karaviti; Mary L Brandt; Monica E Lopez; Prakash Masand; Sridevi Devaraj; John Hicks; Lauren Anderson; Maya Lodish; Meg Keil; Constantine A Stratakis
Journal:  Int J Pediatr Endocrinol       Date:  2015-08-26

10.  Hypercoagulability in Cushing Syndrome, Prevalence of Thrombotic Events: A Large, Single-Center, Retrospective Study.

Authors:  Maria Gabriela Suarez; Madeleine Stack; Jose Miguel Hinojosa-Amaya; Michael D Mitchell; Elena V Varlamov; Chris G Yedinak; Justin S Cetas; Brett Sheppard; Maria Fleseriu
Journal:  J Endocr Soc       Date:  2019-12-15
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.